Akebia Therapeutics (AKBA)
(Real Time Quote from BATS)
$1.37 USD
+0.02 (1.48%)
Updated Aug 15, 2024 09:58 AM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Brokerage Reports
Akebia Therapeutics, Inc. [AKBA]
Reports for Purchase
Showing records 41 - 60 ( 81 total )
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
New Guard Takes Charge of the Strengthened Company; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vadadustat Could Reduce Lung Injury in COVID-19 Patients With ARDS; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
VAFSEO (vadadustat) Approved in Japan; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
New CFO Complements Akebia''s Transition to a Commercial Launch Phase Company
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Impressive Phase 3 Data Elevates Vadadustat''s Potential; Raise PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Fortifies Vadadustat Supply Chain With Third Supply Agreement; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Akebia Enters a Defining Year Poised for Success; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
PRV Purchase for Vadadustat to Meaningfully Improve Its Competitive Position; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
3Q19 Recap: Value Creation Approaches With Vadadustat Readouts by Mid-2020; Moderate PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Enough Is Enough- Akebia Sues CMS Over Decision on Auryxia; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
The Countdown Begins: Global Phase 3 Vadadustat Program Fully Enrolled; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
2Q19 Recap: Vadadustat''s Full Pivotal Data Set a Year Away; Auryxia Growth Finds Its Footing; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Auryxia Patent Settlement With Par Reduces Our Estimated LOE; PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vadadustat NDA Submitted in Japan; Model Refresh; Moderating PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Study Supports Outcomes Benefit on Auryxia; Moderating Sales Trajectory; PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
1Q19 Recap; Competitor Stumble on MACE Highlights Clean Trial Design and Safety Profile of Vadadustat; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Putative Case of Hy''s Law Misunderstood; Adding Auryxia to Model; Raise PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E